LÃ;szlÃ³ Dézsi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4402303/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNAÂvaccine-inducedÂrare (pseudo) allergic reactions: complement activation as a possible contributing factor. GeroScience, 2022, 44, 597-618.	2.1	26
2	Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 34, 102366.	1.7	7
3	A porcine model of hemodialyzer reactions: roles of complement activation and rinsing backÂof extracorporeal blood. Renal Failure, 2021, 43, 1609-1620.	0.8	5
4	Nanostructured lipid carriers accumulate in atherosclerotic plaques of ApoEâ^'/â^' mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 25, 102157.	1.7	7
5	Safety and efficacy of placement of tunneled hemodialysis catheter without the use of fluoroscopy. Clinical Nephrology, 2020, 94, 237-244.	0.4	3
6	Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions. ACS Nano, 2019, 13, 9315-9324.	7.3	127
7	SP539PORCINE CARPA MODEL TO STUDY HYPERSENSITIVITY-LIKE REACTIONS DURING DIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	1
8	Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy. Molecules, 2019, 24, 3283.	1.7	12
9	Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases. European Journal of Medicinal Chemistry, 2019, 184, 111710.	2.6	11
10	<p>Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice</p> . International Journal of Nanomedicine, 2019, Volume 14, 1563-1573.	3.3	18
11	Pharmaceutical Development and Safety Evaluation of a CMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases. Marine Drugs, 2019, 17, 699.	2.2	22
12	Environmental stress and vestibular inputs modulate cardiovascular responses to orthostasis in hypertensive rats. Hypertension Research, 2018, 41, 18-26.	1.5	2
13	From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. Cardiovascular Research, 2018, 114, 1714-1727.	1.8	63
14	Dextran-coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging: evaluation of size-dependent imaging properties, storage stability and safety. International Journal of Nanomedicine, 2018, Volume 13, 1899-1915.	3.3	105
15	A porcine model of complement activation-related pseudoallergy to nano-pharmaceuticals: Pros and cons of translation to a preclinical safety test. Precision Nanomedicine, 2018, 1, 63-73.	0.4	22
16	Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging. International Journal of Nanomedicine, 2017, Volume 12, 5223-5238.	3.3	82
17	Hepatoprotective liposomal glycyrrhizin in alcoholic liver injury. European Journal of Integrative Medicine, 2016, 8, 23-28.	0.8	7
18	Liposomal doxorubicin: the good, the bad and the not-so-ugly. Journal of Drug Targeting, 2016, 24, 765-767.	2.1	11

LÃiszlÃ³ Dézsi

#	Article	IF	CITATIONS
19	Nanoparticles for intravascular applications: physicochemical characterization and cytotoxicity testing. Nanomedicine, 2016, 11, 597-616.	1.7	57
20	Rodent models of complement activation-related pseudoallergy: Inducers, symptoms, inhibitors and reaction mechanisms. European Journal of Nanomedicine, 2015, 7, .	0.6	6
21	Complement activation-related pseudoallergy: insights into a stress reaction to nanomedicines in blood. European Journal of Nanomedicine, 2015, 7, 1.	0.6	0
22	Paradoxical rise of hemolytic complement in the blood of mice during zymosan- and liposome-induced CARPA: a pilot study. European Journal of Nanomedicine, 2015, 7, .	0.6	5
23	Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: Comparison of the porcine and rat responses. Journal of Controlled Release, 2014, 195, 2-10.	4.8	79
24	Cardiopulmonary and hemodynamic changes in complement activation-related pseudoallergy. Health, 2013, 05, 1032-1038.	0.1	6
25	Assessment of the effects of NS11394 and L-838417, α2/3 subunit-selective GABAA receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function. Behavioural Pharmacology, 2012, 23, 790-801.	0.8	17
26	Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath. European Journal of Pharmacology, 2010, 641, 135-141.	1.7	35
27	Antinociceptive desensitizing actions of TRPV1 receptor agonists capsaicin, resiniferatoxin and <i>N</i> â€oleoyldopamine as measured by determination of the noxious heat and cold thresholds in the rat. European Journal of Pain, 2010, 14, 480-486.	1.4	31
28	Both sustained orthostasis and inverse-orthostasis may elicit hypertension in conscious rat. Acta Astronautica, 2007, 60, 415-419.	1.7	0
29	Development of Organic Nitrates for Coronary Heart Disease. , 2006, , 247-258.		0
30	Importance of extracardiac α1-adrenoceptor stimulation in assisting dofetilide to induce torsade de pointes in rabbit hearts. European Journal of Pharmacology, 2006, 537, 118-125.	1.7	19
31	Inverse-Orthostasis May Induce Elevation of Blood Pressure due to Sympathetic Activation. Journal of Cardiovascular Pharmacology, 2006, 47, 287-294.	0.8	9
32	Nitric oxide modulates the interaction of pressure-induced wall mechanics and myogenic response of rat intramural coronary arterioles. Acta Physiologica Hungarica, 2006, 93, 1-12.	0.9	1
33	Experimental Orthostasis Elicits Sustained Hypertension, Which Can Be Prevented by Sympathetic Blockade in the Rat. Journal of Cardiovascular Pharmacology, 2005, 45, 354-361.	0.8	12
34	Effect of a neuroprotective drug, eliprodil on cardiac repolarisation: importance of the decreased repolarisation reserve in the development of proarrhythmic risk. British Journal of Pharmacology, 2004, 143, 152-158.	2.7	18
35	Time related changes in calcium handling in the isolated ischemic and reperfused rat heart. Molecular and Cellular Biochemistry, 2003, 250, 115-124.	1.4	9
36	Prostacyclin-mediated compensatory mechanism in the coronary circulation during acute NO synthase blockade. Life Sciences, 2003, 73, 1141-1149.	2.0	9

LÃiszlÃ³ Dézsi

#	Article	IF	CITATIONS
37	QT prolongation by non-cardiovascular CNS targeting drugs in the rabbit heart in vitro and in vivo. Journal of Molecular and Cellular Cardiology, 2002, 34, A20.	0.9	0
38	Preparation of Intramural Small Coronary Artery and Arteriole Segments and Resistance Artery Networks from the Rat Heart for Microarteriography and for in Situ Perfusion Video Mapping. Microvascular Research, 2001, 61, 282-286.	1.1	26
39	Evidence for the expression of cyclooxygenase-2 enzyme in periodontitis. Life Sciences, 2001, 70, 279-290.	2.0	44
40	Concomitant accumulation of intracellular free calcium and arachidonic acid in the ischemic-reperfused rat heart. Molecular and Cellular Biochemistry, 2001, 226, 119-128.	1.4	17
41	Pharmacologic Inhomogeneity Between the Reactivity of Intramural Coronary Arteries and Arterioles. Journal of Cardiovascular Pharmacology, 2001, 38, 584-592.	0.8	21
42	Fibrinolytic actions of ACE inhibitors: a significant plus beyond antihypertensive therapeutic effects. Cardiovascular Research, 2000, 47, 642-644.	1.8	12
43	Segmental Differences in Geometric, Elastic and Contractile Characteristics of Small Intramural Coronary Arteries of the Rat. Journal of Vascular Research, 1998, 35, 332-344.	0.6	20
44	Somatostatin induces vasodilatation in the cat mesenteric artery via endothelium-derived nitric oxide and prostaglandins. Pflugers Archiv European Journal of Physiology, 1997, 433, 536-538.	1.3	9
45	Effect of a new nitric oxide donor on the biomechanical performance of the isolated ischaemic rat heart. Acta Physiologica Scandinavica, 1997, 161, 55-61.	2.3	14
46	Nitric oxide-dependent opposite effects of somatostatin on arterial and venous caliber in situ. American Journal of Physiology - Heart and Circulatory Physiology, 1996, 271, H2238-H2245.	1.5	3
47	Prolonged effects of MK-801 in the cat during focal cerebral ischemia and recovery: Survival, EEG activity and histopathology. Journal of the Neurological Sciences, 1994, 121, 110-120.	0.3	26
48	Acute Improvement in Histological Outcome by MK-801 following Focal Cerebral Ischemia and Reperfusion in the Cat Independent of Blood Flow Changes. Journal of Cerebral Blood Flow and Metabolism, 1992, 12, 390-399.	2.4	41
49	The Effect of Calcium Entry Blocker S-Emopamil on Cerebrocortical Metabolism and Blood Flow Changes Evoked by Graded Hypotension. Advances in Experimental Medicine and Biology, 1989, 248, 461-470.	0.8	1
50	Selective inhibition of endothelium-dependent dilation in resistance-sized vessels in vivo. American Journal of Physiology - Heart and Circulatory Physiology, 1987, 253, H234-H239.	1.5	17
51	Role of fluid replacement, increased oxygen availability by perfluorochemicals and enhanced RES function in the treatment of mesenteric occlusion shock. Research in Experimental Medicine, 1987, 187, 451-459.	0.7	6
52	Effect of Somatostatin on Intestinal Microcirculation and Metabolism. Advances in Experimental Medicine and Biology, 1984, 169, 551-560.	0.8	2